Article PDF
Avoid common mistakes on your manuscript.
References
Rothschild SI, Gautschi O. Maintenece therapy for patients with advanced non-small celll lung cancer: who to treat and how to treat? memo, 4: 19–22, 2011
Azzoli C, Baker S, Temin S, et al. Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol, 27: 6251–6266, 2009
D'Addario G, Fruh M, Reck M, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol, 21: v116–v119, 2010
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-small Cell Lung Cancer. Version 3.2011. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed January 23, 2011
Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol, 11: 521–529, 2010
Cappuzzo F, Ciuleanu T, Park K, Wu Y, et al. Giaccone G. Erlotinib maintenance therapy in patients with stable disease after first-line platinum-doublet chemotherapy for advanced NSCLC. Ann Oncol, 21(Suppl. 8): 369PD, 2010
Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol, 20: 1335–1343, 2002
Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol, 19: 1336–1343, 2001
Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol, 28: 15s, 2010 (suppl; abstr 7507)
Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind, phase 3 study. Lancet, 374: 1432–1440, 2009
Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol, 27: 591–598, 2009
Belani C, Waterhouse D, Ghazal H, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 28: 15s, 2010 (suppl; abstr 7506)
Brugger W, Kim J, Hansen O, et al. Molecular markers and clinical outcome with erlotinib: results from the phase III placebo-controlled SATURN study of maintenance therapy for advanced NSCLC (abstr B9.1). 13th World Conference on Lung Cancer, San Francisco. Available from: http://www.2009worldlungcancer.org/. (Accessed January 29, 2011)
Temel JS, Greer J, Gallagher E, et al. Effect of early palliative care (PC) on quality of life (QOL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: Results of a phase III randomized trial. J Clin Oncol, 28: 15s, 2010 (suppl; abstr 7509)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dediu, M. Maintenance therapy for patients with advanced non-small cell lung cancer: fact or myth?. memo 4, 1–2 (2011). https://doi.org/10.1007/s12254-011-0244-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-011-0244-9